Skip to main content
. 2015 Jun 5;9(9):1760–1772. doi: 10.1016/j.molonc.2015.05.007

Figure 6.

Figure 6

MvDN30‐PEG20 inhibits HGF‐independent tumor growth in vivo. (A) HGF‐independent Hs746T tumors, prevention trial. Cells were inoculated subcutaneously into the flank of CD1 nu/nu mice; animals were immediately randomized into four groups and treated as follows: Vehicle (CTRL), mDN30 mAb, MvDN30 and MvDN30‐PEG20. (B) HGF‐independent Hs746T tumors, regression trial. Cells were inoculated subcutaneously into the flank of CD1 nu/nu mice and after 31 days animals were randomized into three arms (n = 8) and treated as follows: Vehicle (CTRL), mDN30 mAb and MvDN30‐PEG20. (C) HGF‐independent M162 ‘xenopatient’, regression trial. Tumor specimens were implanted subcutaneously into the flank of NOD/SCID mice; after 24 days animals were randomized into four groups and treated as follows: Vehicle (CTRL), Cetuximab, MvDN30‐PEG20 and MvDN30‐PEG20 + Cetuximab. Each symbol represents the average tumor volume at the indicated time point; bars: standard deviations. *, Student's t Test P < 0.05 **, Student's t Test P < 0.01.